Tag Archives: Cancer

FDA to Review Prostate Cancer Meds

By George Koroneos | Published: May 4, 2010
Image via Wikipedia FDA, on Monday, announced that it was reviewing whether a certain class of prostate cancer drugs could lead to diabetes, stroke, death, or heart problems. The drugs in question are gonadotropin-Releasing Hormone (GnRH) agonists, marketed under a number of monikers, including Vantas and Lupron. These treatments are used to slow the growth of prostate [...]
Posted in FDA, Safety | Also tagged , , , , , , | Leave a comment

Merck, Lilly, Pfizer: One for All and All for One

By Oriana Schwindt | Published: February 24, 2010
Just a month after Andrew Witty’s announcement that GSK will make more than 13,500 of its malaria compounds available to all, Pfizer, Merck, and Eli Lilly have thrown their do-gooder hats into the ring as well. Together, the three drug giants will pull together an undisclosed dollar amount in seed funding and create the independent, non-profit [...]
Posted in Strategy | Also tagged , , , , , , | 1 Comment

Dendreon Picks Bishop as COO

By George Koroneos | Published: December 14, 2009
Congratulations are in order for Hans Bishop, one of our 2009 emerging leaders. Dendreon just announced that it appointed Bishop chief operating officer in charge of the pending launch of the prostate cancer treatment Provenge. “Hans’ extensive and successful global commercial experience will add tremendous value to Dendreon’s already strong executive team as we prepare for [...]
Posted in People | Also tagged , , , , , , , | Leave a comment

Q&A with Steven Paul: Lilly’s New Development Plan

By George Koroneos | Published: September 23, 2009
Last week, Lilly announced a major restructuring plan focused around the creation of one Developmental Center of Excellence and several individual business units. The media (Pharm Exec included) focused on the news that 5,500 jobs were being cut as part of the plan. This week, we’re talking to Lilly to find out what the company’s [...]
Posted in Strategy | Also tagged , , , , , , | 3 Comments

FDA Strengthens Warnings on TNF Inhibitors

By George Koroneos | Published: August 5, 2009
On Tuesday, FDA announced that makers of tumor necrosis factor (TNF) blockers must change their labels to include boxed warnings for “increased risk of lymphoma and other malignancies in children and adolescents.” That’s in addition to the current box warning that the drugs might lead to cancer. TNF blockers (or inhibitors) are used to reduce [...]
Posted in News | Also tagged , , , , , | 1 Comment